Purpose Combination treatment with immune checkpoint inhibitors has shown enhanced
antitumor activity compared with monotherapy in tumor types such as melanoma. The open-…

… At the 3.6 mg/m 2 /d dose level, three patients were treated initially without a DLT and
one patient was entered at the next highest dose level of 6.0 mg/m 2 /d. At this dose on day 3 …

Patients with glioblastoma multiforme (GBM) are profoundly immunosuppressed and may
benefit from restoration of an antitumor immune response in combination with conventional …

… We recommend the following empiric sorafenib starting doses by cohort: cohort 1, 400 mg
twice a day; cohort 2, 400 mg twice a day; cohort 3, 400 mg twice a day; cohort 4, 200 mg twice …

Background Combination treatment with immune checkpoint inhibitors and antiangiogenic
drugs has shown encouraging preliminary antitumor activity across various tumor types …

… After completion of the initial part of the study on day 16, patients began daily treatment
with lapatinib (1,500 mg or lower at the discretion of the clinical investigator) administered at …

BACKGROUND AND PURPOSE: The FLAIR (fluid-attenuated inversion-recovery) pulse
sequence has been shown to be sensitive to abnormalities of the subarachnoid space. Our …

PURPOSE MDX-210 is a bispecific antibody that binds simultaneously to type I Fc receptors
for immunoglobulin G (IgG) (Fc gamma RI) and to the HER-2/neu oncogene protein product. …

… Each patient was treated either once daily or twice daily during a 28-day cycle, and treatment
was continued in the absence of disease progression or unacceptable toxicity. Clinic visits …

A patient with refractory Crohn's disease had two separate episodes of bone marrow suppression
while receiving 50 to 75 mg 6‐mercaptopurine a day and 1000 to 1750 mg olsalazine …